Post Exercise InflammationPhase 3NCT06436781
Effect of Maolactin™ FMR on Exercise Recovery, Inflammation, and Muscle Comfort in an Otherwise Healthy Population
A Phase 3 study testing Maolactin and Maltodextrin in people with Post Exercise Inflammation and Exercise Recovery, run by RDC Clinical Pty Ltd at 1 site in Australia.
Trial summary
This is a double blind, randomised, placebo-controlled, parallel-group trial to evaluate the effect of Maolactin FMR supplementation on post exercise inflammation, exercise recovery and muscle fatigue and pain in an otherwise healthy population of adults 18-65 years old over 10 weeks with 8 weeks of supplementation. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Post Exercise Inflammation, Exercise Recovery, Muscle Fatigue
- What is being tested?
- Maolactin and Maltodextrin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 33 participants
- Where
- 1 siteAustralia
- Study dates
- 12 Sep 2024to 23 May 2025
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults 18-65 years old
- Generally healthy
- BMI 19.0 - 29.9 kg/m2
- Able to provide informed consent
- Generally active, low to moderately trained (with a minimum of 1 resistance exercise sessions per week)
- Agree not to change current diet and/or exercise frequency or intensity during study period
- Agree to not participate in another clinical trial while enrolled in this trial
Who cannot join
- Undertaking high intensity exercise training and or undertaking more than 3 days of resistance training per week.
- Serious illness(1) e.g., mood disorders such as depression, anxiety or bipolar disorder, neurological disorders such as MS, kidney disease, liver disease or heart conditions
- Unstable illness(2) e.g., diabetes and thyroid gland dysfunction
- Unstable intake of any medication or supplement(3)
- Acute injuries on reporting area
- Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years
Show all 17Show fewer
- Currently taking Coumadin (Warfarin), Heparin, Dalteparin, Enoxaparin or other anticoagulation therapy including low dose aspirin
- Receiving medications known to affect inflammation such as steroids
- Active smokers, nicotine use or drug (prescription or illegal substances) abuse
- Chronic past and/or current alcohol use (>21 alcoholic drinks per week)
- Pregnant or lactating women
- Allergic to any of the ingredients in active or placebo formula
- Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month
- Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion
- A serious illness is a condition that carries a risk of mortality, negatively impacts quality of life and daily function and/or is burdensome in symptoms and/or treatments.
- An unstable illness is any illness that is currently not being treated with a stable dose of medication or is fluctuating in severity.
- An unstable intake is any dose that has changed by more than 10% of the previous dose in the past 4-weeks
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of Maolactin™ FMR Supplementation on Exercise Recovery, Inflammation, and Muscle Comfort in an Otherwise Healthy Population: A Double-blind Randomized Placebo-controlled Study
This is a double blind, randomised, placebo-controlled, parallel-group trial to evaluate the effect of Maolactin FMR supplementation on post exercise inflammation, exercise recovery and muscle fatigue and pain in an otherwise healthy population of adults 18-65 years old over 10 weeks with 8 weeks of supplementation.
This is PART A of the study.
- Being tested
- Maolactin, Maltodextrin
- Medical subject headings
- Myalgia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MaolactinDrug
Once daily dose of 2 capsules containing a total of 500mg/day Maolactin
MaltodextrinDrug
Once daily dose of 2 capsules of Maltodextrin containing a total of 0mg/day Maolactin
| Study group | Role | What they receive |
|---|---|---|
| Maolactin | Experimental | 2 capsules containing a total of 500 mg/day active proteins taken once daily before the morning meal Receives: Drug: Maolactin |
| Maltodextrin | Placebo comparator | 2 capsules containing maltodextrin (0mg/day active proteins) taken once daily before the morning meal Receives: Drug: Maltodextrin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in post exercise muscle breakdown
Change in post exercise muscle breakdown as assessed by creatine kinase (CK) via blood test
Measured: Baseline (Pre-exercise and 0, 1, 2, 24 and 48 hours post exercise) and Week 8 (Pre-exercise and 0, 1, 2, 24 and 48 hours post exercise)
Secondary outcomes (36)
Change in Weight
Change in Weight as measured by digital scales
Measured: Baseline and Week 8
Change in Body Mass Index (BMI)
Change in BMI as assessed by digital scale for weight and stadiometer for height
Measured: Baseline and Week 8
Change in Musculoskeletal Health Questionnaire (MSK-HQ)
Change in MSK-HQ as self-reported by participants. Scored on a range of 0-56, with a higher score indicating health status.
Measured: Baseline (Session 1, Session 2 (+24 hours), Session 3 (+48 hours)) and Week 8 (Session 1, Session 2 (+24 hours), Session 3 (+48 hours))
Change in Visual Analogue Scale (VAS) Muscle Pain
Change in VAS Muscle Pain as self-reported by participants. Minimum score = 0, Maximum score = 10. Higher scores indicate a higher level of muscle pain.
Measured: Baseline (Session 1, Session 2 (+24 hours), Session 3 (+48 hours)) and Week 8 (Session 1, Session 2 (+24 hours), Session 3 (+48 hours))
Change in Visual Analogue Scale (VAS) Pain
Change in VAS Pain as self-reported by participants. Minimum score = 0, Maximum score = 10. Higher scores indicate a higher level of pain
Measured: Baseline (Session 1, Session 2 (+24 hours), Session 3 (+48 hours)) and Week 8 (Session 1, Session 2 (+24 hours), Session 3 (+48 hours))
Change in Visual Analogue Scale (VAS) Fatigue
Change in VAS Fatigue as self-reported by participants. Minimum score = 0, Maximum score = 10. Higher scores indicate a higher level of fatigue.
Measured: Baseline (Session 1, Session 2 (+24 hours), Session 3 (+48 hours)) and Week 8 (Session 1, Session 2 (+24 hours), Session 3 (+48 hours))
Change in Visual Analogue Scale (VAS) Mobility
Change in VAS Mobility as self-reported by participants. Minimum score = 0, Maximum score = 10. Higher scores indicate a higher level of mobility.
Measured: Baseline (Session 1, Session 2 (+24 hours), Session 3 (+48 hours)) and Week 8 (Session 1, Session 2 (+24 hours), Session 3 (+48 hours))
Change in Visual Analogue Scale (VAS) Stiffness
Change in VAS Stiffness as self-reported by participants. Minimum score = 0, Maximum score = 10. Higher scores indicate a higher level of stiffness.
Measured: Baseline (Session 1, Session 2 (+24 hours), Session 3 (+48 hours)) and Week 8 (Session 1, Session 2 (+24 hours), Session 3 (+48 hours))
Change in Multidimensional Fatigue Inventory (MFI)
Change in MFI as self-reported by participants. Comprises 20 questions rated on a 5 point scale. with a higher score indicating a higher level of fatigue.
Measured: Baseline (Session 1, Session 2 (+24 hours), Session 3 (+48 hours)) and Week 8 (Session 1, Session 2 (+24 hours), Session 3 (+48 hours))
Change in The Perceived Recovery Status Scale (PRSS)
Change in PRSS as self-reported by participants. A single-item, 0 to 10 point scale where 0 = very poorly recovered (poor performance) and 10 = fully recovered (optimal performance).
Measured: Baseline (Session 1, Session 2 (+24 hours), Session 3 (+48 hours)) and Week 8 (Session 1, Session 2 (+24 hours), Session 3 (+48 hours))
Change in Blood Pressure (BP)
Change in BP as assessed by digital blood pressure monitor
Measured: Baseline and Week 8
Change in Heart Rate (HR)
Change in HR as assessed by digital heart rate monitor
Measured: Baseline (Time 0 and every 5 minutes until return to baseline) and Week 8 (Time 0 and every 5 minutes until return to baseline)
Change in Oxygen Saturation
Change in Oxygen Saturation as measured by pulse oximeter
Measured: Baseline and Week 8
Change in Cytokines
Change in Cytokines as measured by blood test
Measured: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in Nuclear Factor KappaB (NF-kB)
Change in NF-kB as measured by blood test
Measured: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in P-selectin
Change in P-selectin as measured by blood test
Measured: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in E-selectin
Change in E-selectin as measured by blood test
Measured: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in Lipoprotein-associated Phospholipase A2 (Lp-PLA2)
Change in Lp-PLA2 as measured by blood test
Measured: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in Intercellular Cell Adhesion Molecule-1 (ICAM-1)
Change in ICAM-1 as measured by blood test
Measured: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in Intercellular Cell Adhesion Molecule-2 (ICAM-2)
Change in ICAM-2 as measured by blood test
Measured: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in Vascular Cell Adhesion Molecule-1 (VCAM-1)
Change in VCAM-1 as measured by blood test
Measured: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1)
Change in PECAM-1 as measured by blood test
Measured: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in Erythrocyte Sedimentation Rate (ESR)
Change in ESR as measured by blood test
Measured: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in Lactate Dehydrogenase (LDH)
Change in LDH as measured by blood test
Measured: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in P38 Mitogen-activated Protein Kinases (P38)
Change in P38 as measured by blood test
Measured: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in Electrolytes and Liver Function Tests (E/LFT)
Change in E/LFT as measured by blood test
Measured: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in Lactic acid
Change in Lactic acid as measured by blood test
Measured: Baseline (Pre-exercise and 0, 1, 2, 24 and 48 hours post exercise) and Week 8 (Pre-exercise and 0, 1, 2, 24 and 48 hours post exercise)
Change in C-reactive protein (CRP)
Change in CRP as measured by blood test
Measured: Baseline (Pre-exercise and 0, 1, 2, 24 and 48 hours post exercise) and Week 8 (Pre-exercise and 0, 1, 2, 24 and 48 hours post exercise)
Change in myoglobin
Change in myoglobin as measured by blood test
Measured: Baseline (Pre-exercise and 0, 1, 2, 24 and 48 hours post exercise) and Week 8 (Pre-exercise and 0, 1, 2, 24 and 48 hours post exercise)
Change in 1 Repetition Max (1-RM)
Change in 1 Repetition Max (1-RM) as assessed by exercise testing
Measured: Baseline (Session 1 and Session 2 (+24 hours)) and Week 8 (Session 1, Session 2 (+24 hours))
Change in Number of Repetitions to Fatigue
Change in Number of Repetitions to Fatigue as assessed by exercise testing
Measured: Baseline (Session 1 and Session 2 (+24 hours)) and Week 8 (Session 1, Session 2 (+24 hours)
Change in Hand Grip Strength
Change in Hand Grip Strength as measured by dynamometer
Measured: Baseline (Session 1, Session 2 (+24 hours), Session 3 (+48 hours)) and Week 8 (Session 1, Session 2 (+24 hours), Session 3 (+48 hours))
Change in BORG Perception of intensity (RPE)
Change in BORG Perception of intensity (RPE) as self-reported by participants. Rates exertion from a scale of 6 (no exertion) to 20 (maximum effort). A rating between 12 to 14 typically reflects a moderate or somewhat hard level of intensity.
Measured: Baseline (Session 1 and Session 2 (+24 hours)) and Week 8 (Session 1, Session 2 (+24 hours)
Change in Adverse Events
Change in Adverse Events self-reported by participants
Measured: 8 week period from enrolment to participant conclusion
Change in Gastrointestinal Tolerance
Change in Gastrointestinal Tolerance as measured by Gastrointestinal Tolerance (GIT) Questionnaire
Measured: 1 week after starting product
Change in diet
Change in diet as assessed by 3 day Diet Recall
Measured: Baseline and Week 8
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 May 2024
- Study start12 Sep 2024
- Primary completion23 May 2025
- Study completion23 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Post Exercise InflammationStudies of the same condition, open and under way.
- More trials run by RDC Clinical Pty LtdThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 33 participants (actual)
Sponsor and investigators
- Lead sponsor
- RDC Clinical Pty Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- David Briskey, PhD, Principal investigator, RDC Clinical Pty Ltd
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06436781
- Sponsor's protocol ID
- MAOJOI(A)
- Status last verified
- Oct 2024
- First submitted
- 24 May 2024
- Last updated
- 25 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Maolactin™ FMR Supplementation on Exercise Recovery, Inflammation, and Muscle Comfort in an Otherwise Healthy Population: A Double-blind Randomized Placebo-controlled Study
- ClinicalTrials.gov ID
- NCT06436781
- Acronym / sponsor ID
- MAOJOI(A)
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 33 participants (actual)
- Lead sponsor
- RDC Clinical Pty LtdIndustry (pharma, biotech, devices)
- Study start
- 12 Sep 2024 (actual)
- Primary completion
- 23 May 2025 (actual)
- Study completion
- 23 May 2025 (actual)
- First posted
- 31 May 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a double blind, randomised, placebo-controlled, parallel-group trial to evaluate the effect of Maolactin FMR supplementation on post exercise inflammation, exercise recovery and muscle fatigue and pain in an otherwise healthy population of adults 18-65 years old over 10 weeks with 8 weeks of supplementation.
This is PART A of the study.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Maolactin | Experimental | Drug: Maolactin2 capsules containing a total of 500 mg/day active proteins taken once daily before the morning meal |
| Maltodextrin | Placebo comparator | Drug: Maltodextrin2 capsules containing maltodextrin (0mg/day active proteins) taken once daily before the morning meal |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Adults 18-65 years old
- Generally healthy
- BMI 19.0 - 29.9 kg/m2
- Able to provide informed consent
- Generally active, low to moderately trained (with a minimum of 1 resistance exercise sessions per week)
Key exclusion criteria (17 listed)
- Undertaking high intensity exercise training and or undertaking more than 3 days of resistance training per week.
- Serious illness(1) e.g., mood disorders such as depression, anxiety or bipolar disorder, neurological disorders such as MS, kidney disease, liver disease or heart conditions
- Unstable illness(2) e.g., diabetes and thyroid gland dysfunction
- Unstable intake of any medication or supplement(3)
- Acute injuries on reporting area
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MaolactinOnce daily dose of 2 capsules containing a total of 500mg/day Maolactin | Drug | Maolactin |
| MaltodextrinOnce daily dose of 2 capsules of Maltodextrin containing a total of 0mg/day Maolactin | Drug | Maltodextrin |
Primary outcome
Change in post exercise muscle breakdown
Time frame: Baseline (Pre-exercise and 0, 1, 2, 24 and 48 hours post exercise) and Week 8 (Pre-exercise and 0, 1, 2, 24 and 48 hours post exercise)
Change in post exercise muscle breakdown as assessed by creatine kinase (CK) via blood test
36 secondary outcomes
Change in Weight
Time frame: Baseline and Week 8
Change in Body Mass Index (BMI)
Time frame: Baseline and Week 8
Change in Musculoskeletal Health Questionnaire (MSK-HQ)
Time frame: Baseline (Session 1, Session 2 (+24 hours), Session 3 (+48 hours)) and Week 8 (Session 1, Session 2 (+24 hours), Session 3 (+48 hours))
Change in Visual Analogue Scale (VAS) Muscle Pain
Time frame: Baseline (Session 1, Session 2 (+24 hours), Session 3 (+48 hours)) and Week 8 (Session 1, Session 2 (+24 hours), Session 3 (+48 hours))
Change in Visual Analogue Scale (VAS) Pain
Time frame: Baseline (Session 1, Session 2 (+24 hours), Session 3 (+48 hours)) and Week 8 (Session 1, Session 2 (+24 hours), Session 3 (+48 hours))
Change in Visual Analogue Scale (VAS) Fatigue
Time frame: Baseline (Session 1, Session 2 (+24 hours), Session 3 (+48 hours)) and Week 8 (Session 1, Session 2 (+24 hours), Session 3 (+48 hours))
Change in Visual Analogue Scale (VAS) Mobility
Time frame: Baseline (Session 1, Session 2 (+24 hours), Session 3 (+48 hours)) and Week 8 (Session 1, Session 2 (+24 hours), Session 3 (+48 hours))
Change in Visual Analogue Scale (VAS) Stiffness
Time frame: Baseline (Session 1, Session 2 (+24 hours), Session 3 (+48 hours)) and Week 8 (Session 1, Session 2 (+24 hours), Session 3 (+48 hours))
Change in Multidimensional Fatigue Inventory (MFI)
Time frame: Baseline (Session 1, Session 2 (+24 hours), Session 3 (+48 hours)) and Week 8 (Session 1, Session 2 (+24 hours), Session 3 (+48 hours))
Change in The Perceived Recovery Status Scale (PRSS)
Time frame: Baseline (Session 1, Session 2 (+24 hours), Session 3 (+48 hours)) and Week 8 (Session 1, Session 2 (+24 hours), Session 3 (+48 hours))
Change in Blood Pressure (BP)
Time frame: Baseline and Week 8
Change in Heart Rate (HR)
Time frame: Baseline (Time 0 and every 5 minutes until return to baseline) and Week 8 (Time 0 and every 5 minutes until return to baseline)
Change in Oxygen Saturation
Time frame: Baseline and Week 8
Change in Cytokines
Time frame: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in Nuclear Factor KappaB (NF-kB)
Time frame: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in P-selectin
Time frame: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in E-selectin
Time frame: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in Lipoprotein-associated Phospholipase A2 (Lp-PLA2)
Time frame: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in Intercellular Cell Adhesion Molecule-1 (ICAM-1)
Time frame: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in Intercellular Cell Adhesion Molecule-2 (ICAM-2)
Time frame: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in Vascular Cell Adhesion Molecule-1 (VCAM-1)
Time frame: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1)
Time frame: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in Erythrocyte Sedimentation Rate (ESR)
Time frame: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in Lactate Dehydrogenase (LDH)
Time frame: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in P38 Mitogen-activated Protein Kinases (P38)
Time frame: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in Electrolytes and Liver Function Tests (E/LFT)
Time frame: Baseline (Pre-exercise and 2 hours post) and Week 8 (Pre-exercise and 2 hours post)
Change in Lactic acid
Time frame: Baseline (Pre-exercise and 0, 1, 2, 24 and 48 hours post exercise) and Week 8 (Pre-exercise and 0, 1, 2, 24 and 48 hours post exercise)
Change in C-reactive protein (CRP)
Time frame: Baseline (Pre-exercise and 0, 1, 2, 24 and 48 hours post exercise) and Week 8 (Pre-exercise and 0, 1, 2, 24 and 48 hours post exercise)
Change in myoglobin
Time frame: Baseline (Pre-exercise and 0, 1, 2, 24 and 48 hours post exercise) and Week 8 (Pre-exercise and 0, 1, 2, 24 and 48 hours post exercise)
Change in 1 Repetition Max (1-RM)
Time frame: Baseline (Session 1 and Session 2 (+24 hours)) and Week 8 (Session 1, Session 2 (+24 hours))
Change in Number of Repetitions to Fatigue
Time frame: Baseline (Session 1 and Session 2 (+24 hours)) and Week 8 (Session 1, Session 2 (+24 hours)
Change in Hand Grip Strength
Time frame: Baseline (Session 1, Session 2 (+24 hours), Session 3 (+48 hours)) and Week 8 (Session 1, Session 2 (+24 hours), Session 3 (+48 hours))
Change in BORG Perception of intensity (RPE)
Time frame: Baseline (Session 1 and Session 2 (+24 hours)) and Week 8 (Session 1, Session 2 (+24 hours)
Change in Adverse Events
Time frame: 8 week period from enrolment to participant conclusion
Change in Gastrointestinal Tolerance
Time frame: 1 week after starting product
Change in diet
Time frame: Baseline and Week 8
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jun 2025.
Related trials for Post Exercise Inflammation
Not yet recruiting
Exercise, Mediterranean Diet and Inflammation in Heart Failure
Heart Failure, Heart Failure Preserved Ejection Fraction
Not yet recruiting
Therapeutic Ultrasound for Muscle Recovery After Muscle Fatigue Exercise
Muscle Fatigue (C23.888.592.612.612), Delayed Onset Muscle Soreness (DOMS)
Not yet recruiting
Does Estrogen Blunt the Effects of Exercise Training on Glycemic Control
To Determine Whether Estrogen Influences the Effects of Training on Glycemic Control and Insulin Sensitivity
Not yet recruiting
Circulatory Exercise After Total Knee Replacement
Total Knee Replacement, Knee Osteoarthritis
Recruiting
Protecting the Brain From Post-Stroke Cognitive Impairment and Dementia With Multimodal Exercise Training
Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David Briskey, PhD principal investigator
RDC Clinical Pty Ltd
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Maolactin and Maltodextrin in people with Post Exercise Inflammation and Exercise Recovery, run by RDC Clinical Pty Ltd at 1 site in Australia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in post exercise muscle breakdown (time frame: Baseline (Pre-exercise and 0, 1, 2, 24 and 48 hours post exercise) and Week 8 (Pre-exercise and 0, 1, 2, 24 and 48 hours post exercise)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jun 2025.